|Page (1) of 1 - 06/19/12||email article||print page|
Market Research Forecasts Hepatitis B Therapeutics Market at $4.4 Billion by 2019(June 19, 2012)
ROCKVILLE, MD -- (Marketwire) -- 06/19/12 -- MarketResearch.com has announced the addition of the new report "Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019," to their collection of Diseases & Conditions market reports. For more information, visit http://www.marketresearch.com/GlobalData-v3648/Hepatitis-Therapeutics-Pipeline-Assessment-Forecasts-6971774/
The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData's analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019.
The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
For more information, visit http://www.marketresearch.com/GlobalData-v3648/Hepatitis-Therapeutics-Pipeline-Assessment-Forecasts-6971774/
MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit http://www.marketresearch.com.
Copyright @ Marketwire
Related Keywords: MarketResearch.com, Marketwire, Surgery, Medical,